Increased COX-2 expression and elevated PGE 2 have been associated with a poor prognosis in lung cancer. Cannabinoids have been known to exert some of their biological effects via modulation of prostaglandin production. We evaluated the impact of methanandamide on COX-2 expression, PGE 2 production, and tumor growth in murine lung cancer. Methanandamide administration (5 mg/kg, four times/wk i.p.) resulted in an increased rate of tumor growth (P<0.01 compared with diluent treated controls). The CB1 and CB2 receptor antagonists, SR141716 and SR144528, did not block the methanandamide-mediated increase in tumor growth. In vivo, methanandamide treatment increased the production of PGE 2 at the tumor site as well as in splenocytes. Consistent with these results, methanandamide increased PGE 2 and COX-2 levels in murine lung cancer cells in vitro via a cannabinoid receptor-independent mechanism. The COX-2-specific inhibitor, SC58236, abrogated methanandamide induction of PGE 2 production in vitro and blocked methanandamide-enhanced tumor growth in vivo. Furthermore, the p38/MAPK inhibitor, SB203528, and the p42/44 inhibitor, PD98059, blocked methanandamide-mediated induction of PGE 2 and COX-2. These results suggest that methanandamide augments tumor growth by a cannabinoid receptor-independent pathway that is associated with the up-regulation of COX-2.
regularly use aspirin (a commonly used COX inhibitor) have been interpreted as supporting this hypothesis (16) (17) (18) .
Cannabinoids are known to modulate arachidonate metabolism; expression of the inducible cyclooxygenase enzyme, COX-2; and prostaglandin formation (19) (20) (21) . The endocannabinoids and their receptors are found in simple organisms such as hydra and in more complex organisms such as mammals (22) . The evolutionarily conserved nature of the endocannabinoids and their receptors suggests that they form a fundamental biological regulatory system. Two specific cannabinoid receptors have been identified. The CB1 receptor, although primarily expressed in the nervous system, is also expressed in other tissues (23, 24) . The CB2 receptor is primarily expressed on cells of the immune system. Hence, the CB2 receptor is believed to be primarily responsible for cannabinoid modulation of immune responses. We have previously reported that THC, acting through the CB2 receptor, inhibits the protective immune response to tumor growth (25) . Endocannabinoids are produced by many cell types and have been reported to be elevated in bladder, prostate, pituitary adenomas, and colon carcinoma tumors (26) (27) (28) (29) . In the present study, we investigated the ability of methanandamide, a stable analog of the endocannabinoid anandamide, to modulate murine lung cancer growth. We report here that methanandamide treatment increases murine lung cancer growth in vivo. The increased tumor growth is accompanied by an increase in PGE 2 production and is not cannabinoid receptor dependent. In addition, the endocannabinoids anandamide and 2-arachidonylglycerol (2-AG) stimulated murine lung cancer cell COX-2 expression and PGE 2 production in vitro. This increased COX-2 metabolism may be responsible for the enhanced tumor growth observed with endocannabinoid treatment.
MATERIALS AND METHODS

Reagents
Methanandamide, anandamide, and 2-arachidonylglycerol were purchased from Biomol (Plymouth Meeting, PA). The CB1 antagonist SR141716 and the CB2 antagonist SR144528 were provided by from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health, Bethesda, MD (K. Davis Jr). The COX-2 inhibitor SC58236 was provided by Pharmacia. The P38/MAPK inhibitor, SB 203508, and the p42/44 MAPK inhibitor, PD98059, were purchased from Tocris Cookson (Ellisville, MO). The COX-2 EIA kit was purchased from Assay Designs (Ann Arbor, MI).
Mice
Pathogen-free male C57BL/6 (H-2 b ) and BALB/c mice (H-2 d ) (8-12 wk of age) were obtained from Harlan (Indianapolis, IN) or Simonsen Laboratories (Gilroy, CA). Mice were maintained in the West Los Angeles Healthcare Center Animal Research Facility. All studies received approval by the institutional animal review committee.
Cell culture
The well-characterized Lewis lung carcinoma (3LL, H-2 b ) and line 1 alveolar cell carcinoma (L1C2, H-2 d ) murine cell lines were used to establish the in vivo models (ATCC, Manassas, VA). Both of these tumor cell lines are weakly immunogenic and evidence progressive tumor growth in vivo (25, 26) . The cells were cultured in complete medium consisting of RPMI (Irvine Scientific, Santa Ana, CA) supplemented with 10% fetal calf serum (FCS) (Gemini Bioproducts, Calabasas, CA), penicillin (100 U/ml), streptomycin (0.1 mg/ml), and 2 mM glutamine (JRH Biosciences, Lenexa, KS) and kept at 37°C in a humidified atmosphere containing 5% CO 2 .
Evaluation of tumorigenicity in vivo
To determine the effect of methanandamide on tumorigenicity in vivo, we pretreated mice with either methanandamide (5 mg/kg) or diluent control four times per week for 2 wk via i.p. injections. Cells (5 × 10 5 3LL or 10 5 L1C2) were then implanted s.c. in the supra-scapular area. Following tumor cell inoculation, mice continued to receive methanandamide or diluent four times per week. Tumor growth was assessed by measuring the diameters of the tumor with calipers as described previously (30) .
PGE 2 determinations by EIA
L1C2 cells were plated at a density of 10 5 cells/ml and treated with methanandamide (13.8 µM), anandamide (14 µM), 2-AG (13 µM), the COX-2 inhibitor SC58236 (1.5, 2.5, 12.4 µM), the CB1 antagonist SR141716 (2 µM), the CB2 antagonist SR144528 (2 µM), the P38 MAPK inhibitor SB2035089 (10 µM), or the p42/44 MAPK inhibitor PD98059 (30 mM). Following a 24-h incubation, tumor supernatants were collected for PGE 2 determination. Reagents for the PGE 2 assay were obtained from Cayman Chemical Company. PGE 2 EIA was performed according to the manufacturer's instructions as routinely performed in our laboratory (31) . A Trypan blue dye exclusion assay was performed to confirm that the concentrations of SC58236, SB203508, PD98059, SR141716, or SR144528 used in the assays were not toxic.
Determination of COX-2 protein expression in vitro
L1C2 murine lung cancer cells were plated at a concentration of 5 × 10 5 cells/ml in 10% FBS/RPMI. Cells were treated with methanandamide, anandamide, 2-AG, the p38 inhibitor SB203508, the p42/44 MAPK inhibitor PD98059, the COX-2 inhibitor SC58236, the CB1 antagonist SR141716, or the CB2 antagonist SR144528 for 24 h. The attached cells were then washed twice with cold phosphate-buffered saline (PBS) and harvested with a cell scraper. The cells were centrifuged, and the resulting pellet was resuspended in 0.5 ml of homogenization buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, 0.25 M sucrose, 1% NP-40, 0.1% SDS, and protease inhibitors [P-8340; Sigma, St. Louis, MO]) and disrupted by sonication using a model 60 Sonic Dismembrator at a setting of 10 for three 10-s pulses (Fisher Scientific, Pittsburgh, PA). The cell extract was clarified by centrifugation and assayed for COX-2 using a COX-2 EIA kit according to the manufacturer's instructions (Assay Designs). Total protein was determined by Bradford protein assay (Sigma).
RESULTS
Methanandamide treatment increases tumor growth in vivo
We have previously shown that THC treatment suppresses the immune response to implanted tumors, resulting in increased tumor growth. This inhibition of immune responsiveness was found to be CB2 receptor-dependent (25) . Because endogenous ligands for the cannabinoid receptors are widely distributed, being found in the central nervous system and in peripheral tissues such as spleen and lung (27, 32) , we were prompted to evaluate the effect of endocannabinoids on tumor growth in vivo. We evaluated the effect of methanandamide, a metabolically stable analog of anandamide, on tumorigenicity in two well-characterized murine tumor models. As shown in Figures 1A and 1B , there was significant enhancement of 3LL and L1C2 tumor growth in methanandamide-treated mice (P < 0.01 and P < 0.05 compared with diluent-treated controls).
Methanandamide-enhanced tumor growth is cannabinoid receptor independent
Cannabinoid receptors have been implicated in both the enhancement and inhibition of tumor cell proliferation (33) (34) (35) (36) . To determine whether methanandamide-enhanced tumor growth involved the CB1 or CB2 cannabinoid receptors, we used cannabinoid receptor antagonists in an attempt to block methanandamide-enhanced tumor growth. Mice were treated with methanandamide in combination with the specific CB1 receptor antagonist SR141716 (1 µg/kg) or the CB2 receptor antagonist SR144528 (1 µg/kg). Neither CB1 nor CB2 receptor antagonism blocked the increased rate of tumor growth observed with methanandamide treatment, suggesting that methanandamide-enhanced tumor growth is cannabinoid receptor independent (Fig. 1C) 
Methanandamide enhances tumor and splenocyte production of PGE 2 in vivo
Increased production of PGE 2 is associated with several different malignancies, including lung cancer. The increased tumor growth associated with elevated PGE 2 could be due to a number of factors, including increased angiogenesis, enhanced tumor invasiveness, inhibition of tumor cell apoptosis, or suppression of host immunity (10, 31, 37) . Based on previous studies demonstrating that cannabinoids increase the production of prostaglandins, we sought to determine whether methanandamide treatment in vivo increases the production of PGE 2 in splenocytes and the amount of PGE 2 present at the tumor site. Splenocytes and tumors from mice treated with methanandamide or diluent control were isolated, and the production of PGE 2 was determined by EIA. We found that methanandamide treatment significantly increased splenocyte PGE 2 production and also increased the level of PGE 2 present at the tumor site (Fig. 2) .
Methanandamide induces tumor cell PGE 2 production and COX-2 expression in vitro
To determine whether tumor cells are a source of the increased PGE 2 present at the tumor site, we evaluated the ability of methanandamide to directly stimulate tumor cell production of PGE 2 and expression of COX-2 in vitro. Following exposure to methanandamide (13.8 µM), L1C2 cells increased PGE 2 production and expression of COX-2, suggesting that the tumor cells are one source of the increased PGE 2 observed in vivo (Fig. 3) .
Methanandamide induction of PGE 2 production is cannabinoid receptor independent
The increased rate of tumor growth observed in methanandamide-treated mice could not be blocked by cannabinoid receptor antagonists, suggesting that methanandamide-mediated increased tumorigenicity is independent of CB1 and CB2 receptor signaling. This observation prompted us to determine whether methanandamide stimulation of tumor cell PGE 2 production in vitro was also independent of cannabinoid receptor signaling. L1C2 cells were cultured with methanandamide in the presence or absence of SR141716 (2 µM) or SR144528 (2 µM), and the production of PGE 2 was determined in the tumor supernatants. Neither CB1 nor CB2 receptor antagonists blocked the capacity of methanandamide to increase PGE 2 production, suggesting a cannabinoid receptor-independent mechanism (Fig. 4) .
Enhanced tumor PGE 2 production is COX-2 dependent
To determine whether the increased production of PGE 2 by tumor cells was COX-2 dependent, we evaluated the ability of the specific COX-2 inhibitor, SC58236, to block methanandamide stimulation of PGE 2 production. L1C2 cells were treated with methanandamide (13.8 µM) in the presence or absence of SC58236 (2.5,µM). COX-2 inhibition blocked PGE 2 production (Fig. 4) 
COX-2 inhibition abrogates methanandamide-mediated increased tumor growth in vivo
The methanandamide-mediated increased tumor growth in vivo was cannabinoid receptor independent. In vitro, methanandamide induction of PGE 2 and COX-2 was also found to be cannabinoid receptor independent. Because elevated COX-2 activity inhibits immune response and increased expression enhances tumor growth, we speculated that administration of the COX-2 inhibitor, SC58236, would abrogate the ability of methanandamide to increase tumor growth. BALB/c mice were treated with methanandamide (5 mg/kg), SC58236 (0.1 mg/kg), methanandamide in combination with SC58236, or diluent control. COX-2 inhibition abrogated methanandamide-mediated increased tumor growth (Fig. 5) .
Methanandamide induction of COX-2 and PGE 2 production is mediated via P38 and p42/44 MAPK signaling pathways
Because it has been reported previously that COX-2 expression can be regulated by p38/MAPK or p42/44 MAPK, we evaluated the ability of p38 and p42/44 inhibition to block PGE 2 production and COX-2 levels in murine lung cancer cells (21, 38, 39) . L1C2 cells were cultured with methanandamide in the presence or absence of the p38 inhibitor SB203580 or the p42/44 inhibitor PD98059. The inhibition of p38 or p42/44 blocked the production of PGE 2 and COX-2 levels (Fig. 6 ).
DISCUSSION
Increasing evidence indicates that tumor COX-2 activity has a multifaceted role in conferring the malignant and metastatic phenotypes. Although multiple genetic alterations are necessary for lung cancer invasion and metastasis, COX-2 may be a central element in orchestrating this process (10-13, 31, 37, 40) . Studies indicate that overexpression of COX-2 is associated with apoptosis resistance (41) (42) (43) (44) , angiogenesis (7, (45) (46) (47) (48) , decreased host immunity (10, 31) , and enhanced tumor invasiveness and metastasis (49) . Thus, COX-2 can influence multiple pathways and mechanisms in lung cancer carcinogenesis. Consistent with the importance of COX-2 in promoting tumorigenicity, the COX-2 inhibitor, celecoxib, significantly decreased tumor growth in the Lewis Lung carcinoma model (50) . In this latter report, COX-2 expression was found predominantly in the tumor-associated vasculature, suggesting that COX-2-derived prostaglandins contribute to tumor growth by inducing neovascularization. COX-2 activity can be detected throughout the progression of a premalignant lesion to the metastatic phenotype (11) . In human NSCLC, overexpression of COX-2 is associated with enhanced invasion, metastasis, and shortened survival (49) . Thus, factors in the tumor microenvironment, such as endocannabinoids, that contribute to COX-2 elevation may promote tumorigenicity.
Cannabinoids are known to modulate arachidonate metabolism and increase the formation of prostaglandins (19, 20, 51) . Cannabinoid regulation of prostaglandin production may be one mechanism by which cannabinoids modulate tumor growth. In vitro studies have shown that exposure to cannabinoids can inhibit tumor cell proliferation (35, 52) . In keeping with these in vitro findings, studies in immunocompromised model systems indicate that local or intratumoral injection of THC or CB2 receptor agonists can inhibit tumor growth (36, 52, 53) . In contrast to these reports, we have previously shown that systemic administration of THC leads to a CB2 receptor-dependent increase in tumor growth in immune competent mice (25) . Because endocannabinoids are present in many tissues, and their receptors are expressed on immune cells (23, 24) , we were prompted to investigate their ability to impact tumor growth in the context of a functioning immune system. The endocannabinoids anandamide and 2-AG were the first identified endogenous cannabinoid receptor ligands (54, 55) . However, because they have short half-lives in vivo, we used a metabolically stable analog of anandamide, methanandamide, for our investigations (56) . Here, we show that methanandamide administration increases the rate of murine lung cancer growth in vivo.
Cannabinoids exert their biological effects via cannabinoid receptor-dependent and -independent pathways. Both the CB1 and CB2 receptors are expressed on cells of the immune system and thus could mediate cannabinoid regulation of immune responses. The CB2 receptor is the predominant cannabinoid receptor expressed by immune cells, being expressed from 3-to 100-fold times the level of the CB1 receptor (23, 57) . We previously reported that THC inhibited the immune response to tumor growth via a CB2-receptor signaling pathway (25) . In contrast to our previous observation with THC, the present findings indicate that the ability of methanandamide to increase tumor growth is not blocked by CB2 receptor antagonism. Because methanandamide is thought to be primarily a CB1 receptor agonist, we used the CB1-specific antagonist, SR141716, to determine whether methanandamide increased tumor progression via CB1 receptor signaling. The methanandamide-induced increase in tumor growth was not CB1 receptor dependent. These results suggest that, in contrast to THC, methanandamide-mediated increased tumor growth occurs via a cannabinoid receptor-independent pathway.
Because endocannabinoids can stimulate arachidonate metabolism, we assessed PGE 2 levels in methanandamide-treated mice. We found that methanandamide treatment led to an increase in murine splenocyte production of PGE 2 . In tumor-bearing mice, we found that methanandamide administration increased the level of PGE 2 both in splenocytes and at the tumor site. To determine the contribution of the tumor to the increased production of PGE 2 , we evaluated the ability of methanandamide to stimulate tumor cell PGE 2 production in vitro. We found that methanandamide increased tumor cell PGE 2 production and COX-2 levels, suggesting that the tumor is one source of the increased PGE 2 . Consistent with our in vivo results demonstrating that methanandamide-enhanced tumor growth is cannabinoid receptor independent, we found that the ability of methanandamide to increase tumor cell PGE 2 production in vitro was also cannabinoid receptor independent. The increased PGE 2 production was dependent on the activity of COX-2 as shown by the ability of COX-2 inhibition to block methanandamide stimulation of PGE 2 production. In addition, we were able to abrogate methanandamide-mediated augmentation of tumor growth in vivo by administration of the COX-2 inhibitor SC58236. Thus, methanandamide induction of COX-2 could influence multiple mechanistic pathways promoting lung cancer tumorigenicity.
In colon carcinoma cells, the levels of anandamide and 2-AG are elevated compared with normal adjacent tissue (29) . Therefore, we investigated in vitro the ability of these endocannabinoids to stimulate tumor cell PGE 2 production and COX-2 levels. We found that anandamide and 2-AG increased murine tumor PGE 2 production and COX-2 protein production (data not shown). Thus, endocannabinoids present in the tumor environment may enhance tumor progression as a function of heightened COX-2 expression. Ramer et al. recently reported that methanandamide stimulates the production of COX-2 via p38 or p42/44 MAP kinase pathways in human neuroglioma cells (21) . In agreement with these findings, we report here that both the p38/MAPK inhibitor SB203508 and the p42/44 MAP kinase inhibitor PD98059 blocked the methanandamide-induced increase in PGE 2 production and COX-2 expression in murine lung cancer cells. Further studies will be required to determine the significance of these observations and the signaling pathways operative in endocannabinoid regulation of COX-2. 2 µM) , and the production of PGE 2 was determined in the tumor supernatants. Cannabinoid receptor antagonists did not block methanandamide induction of PGE 2 production. To determine whether methanandamide mediated elevation of PGE 2 is COX-2 dependent, we incubated cells in the presence of the COX-2 inhibitor SC52836 (2.5 µM). Cox-2 inhibition abrogated methanandamide induction of PGE2 production (n=3). cells were plated at a density of 10 5 cells/ml and treated with methanandamide (13.8 µM), methanandamide plus the P38 MAPK inhibitor SB2035089 (10 µM), the p42/44 MAPK inhibitor PD98059 (30 mM), or diluent control. Following a 24-h incubation, tumor supernatants were collected for PGE 2 determination and the cells were harvested for COX-2 ELISA. Inhibition of the MAPK signaling pathway prevented methanandamide induction of PGE2 and COX-2 levels (*P<0.01).
